Navigation Links
Gene therapy corrects sickle cell disease in laboratory study
Date:12/3/2008

Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology. In their studies, the researchers found that the treated mice showed essentially no difference from normal mice. Although the scientists caution that applying the gene therapy to humans presents significant technical obstacles, they believe that the new therapy will become an important treatment for the disease.

Sickle cell disease, which affects millions of people worldwide, arises because of a tiny genetic defect in the gene for beta-globin, a protein component of hemoglobin. This defect causes hemoglobin-containing red blood cells to tend to deform, clump and break apart. The resulting clogged blood vessels can lead to cognitive dysfunction by causing small strokes in the brain and cause damage to kidneys, liver, spleen and lungs. The only permanent cure for the disease is a bone marrow transplant to give recipients blood-forming cells that will form normal beta-globin. However, such transplants are rare because of the lack of compatible donors.

Researchers have long known that symptoms of the disease could be alleviated by persistence in the blood of an immature fetal form of hemoglobin in red blood cells. This immature hemoglobin, which usually disappears after birth, does not contain beta-globin, but another form called gamma-globin. St. Jude researchers had found that treating patients with the drug hydroxyurea encourages the formation of fetal hemoglobin and alleviates disease symptoms.

"While this is a very useful treatment for the disease, our studies indicated that it might be possible to cure the disorder if we could use gene transfer to permanently increase fetal hemoglobin levels," said Derek Persons, M.D., Ph.D., assistant member in the St. Jude Department of Hematology.

He and his colleagues developed a technique to insert the gene for gam
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A new radiation therapy treatment developed for head and neck cancer patients
2. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. MIT works toward safer gene therapy
5. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
6. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
7. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
8. Safe and effective therapy discovered for patients with protein-losing enteropathy
9. Ireland Cancer Center researchers advance stem cell gene therapy
10. Dolphin therapy a dangerous fad, Emory researchers warn
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... use increasingly threatening signals to ward off trespassing rivals. First ... waving a bird,s version of "flipping the bird" ... signals have failed, attack. This hierarchical warning scheme, ... to a communication system that has been long-used as a ...
... SHREWSBURY, MA -- A study published today in ... presented compelling data showing the consumption of both high fructose ... with average daily consumption do not increase liver fat in ... The findings also add to an already well-established body of ...
... and trainers as career killers, Achilles tendon injuries are among ... nuclear fallout in post WWII tests, scientists have learned why: ... Achilles tendon is a tissue that does not repair itself. ... Journal . "Tendon injury is a very common ...
Cached Biology News:'Get off my lawn:' Song sparrows escalate territorial threats - with video 2'Get off my lawn:' Song sparrows escalate territorial threats - with video 3New study finds neither HFCS nor table sugar increases liver fat under 'real world' conditions 2Fallout from nuclear testing shows that the Achilles tendon can't heal itself 2
(Date:5/21/2015)... 2015 Seventh Wave Laboratories, a consulting-based ... of pharmaceutical products and medical devices, announced the purchase ... a 50,000 sq. ft. building more than three times ... growth. Facility renovations will begin immediately and the gradual ... occur in September. , “We are excited about ...
(Date:5/21/2015)... May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... striving to become a leader in the development of ... that the final CVac data from the Phase II ... trend for a clinically meaningful improvement in Overall Survival ... patients. In the group of second remission ...
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM) announced that ... LLC for the purpose of resolving the patent infringement ... entered into a licensing arrangement with DataSci. OmniComm ... have come to an agreement in this matter. ...
... (NasdaqGS: VARI) plans to release its financial results for the ... Pacific Time (PT) on Wednesday, April 29, 2009. A live ... review those quarterly results is scheduled to follow at 2:00 ... from Varian, Inc.,s Web site at www.varianinc.com ...
... BUDAPEST, Hungary, April 15 ChemAxon, a software,solutions ... version,5.2 of their cheminformatics toolkits, Marvin & JChem. ... options and improvements in search,performance. , ... suite of application programming interfaces,(API,s) and graphic user ...
Cached Biology Technology:OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks 2
... LC Sciences provides a comprehensive epitope ... microarrays synthesized on Paraflo microfluidic chips ... biosensor development. This comprehensive service includes ... assays using sample(s) provided by you, ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly ... proteins in E. coli (1). The GSTTag ... production and in some cases the solubility ... a soluble, properly folded form, GSTTag fusion ...
... used as a fusion partner when expressing ... sequence has been reported to enhance the ... of its fusion partners. When expressed in ... proteins can be purified with immobilized glutathione. ...
... Cell Kit with Medium High quality ready-to-use ... optimized base medium for growth and lineage ... cells generated from E18 fetal rat brain ... tissue-like mixture of in vitro stem/progenitor cells, ...
Biology Products: